⚠ Separation Costs Before Separation BenefitsLow threat

Johnson & Johnson (JNJ) — threat to the moat

J&J has spent about $1.4 billion reorganising and separating a business it is giving away.

Separating a $9 billion business costs money before it saves any. J&J recorded orthopaedics separation-related costs of $0.3 billion in the second quarter of 2026 and $0.4 billion in the first half1. A separate orthopaedics restructuring programme, begun in 2023 to exit certain markets, product lines and distribution arrangements, will be completed in the fourth quarter of 2026 at a total cost of approximately $1 billion2.

Orthopaedics restructuring and separation costs ($M)~1,000Restructuring programme total400Separation costs H1 2026300Separation costs Q2 2026J&J Form 10-Q and financial schedules, Q2 2026
Costs arrive before the separation does.

Those costs are excluded from adjusted earnings3, which makes them easy to overlook. They are real cash spent on reorganising a business J&J is giving away.

The separation also carries execution risk. The company lists its ability to successfully separate the orthopaedics business among its risk factors4, and the target window of 18 to 24 months from October 20255 ends in 2027.

The business also carries legal exposure into its separation. In June 2026 three relators filed an amended False Claims Act complaint in Florida alleging that the company and DePuy Synthes, along with a hospital operator and two medical centres, caused the submission of false claims6. It is an allegation, not a finding, but it is the kind of liability that must be allocated between parent and spin-off.

The costs sit outside the numbers management emphasises. J&J excludes orthopaedics separation-related items from adjusted earnings, $258 million in the second quarter and $377 million in the first half of 20267. They are real expenses, and a separation that runs long keeps adding them.

The deadline is the test: the separation should complete inside that window. Slipping past October 2027 would mean the costs keep running and the promised lift to J&J's margins is deferred.

References
  1. ReportedJ&J recorded orthopaedics separation-related costs of $0.3 billion in the second quarter of 2026 and $0.4 billion in the first half.
    Johnson & Johnson Form 10-Q for the quarter ended 28 June 2026 - segment income, talc, net debt, repurchases and equity. — Q2 2026 · publ. 23 July 2026 · source ↗
  2. ReportedA separate orthopaedics restructuring programme, begun in 2023 to exit certain markets, product lines and distribution arrangements, will be completed in the fourth quarter of 2026 at a total cost of approximately $1 billion.
    Johnson & Johnson second-quarter 2026 supplementary sales data, statement of earnings and non-GAAP reconciliation, Form 8-K exhibit 99.2 - statement of earnings and non-GAAP reconciliation. — Q2 2026 · publ. 15 July 2026 · source ↗
  3. ReportedThose costs are excluded from adjusted earnings, which makes them easy to overlook.
    Johnson & Johnson second-quarter 2026 supplementary sales data, statement of earnings and non-GAAP reconciliation, Form 8-K exhibit 99.2 - statement of earnings and non-GAAP reconciliation. — Q2 2026 · publ. 15 July 2026 · source ↗
  4. ReportedThe company lists its ability to successfully separate the orthopaedics business among its risk factors, and the target window of 18 to 24 months from October 2025 ends in 2027.
    Johnson & Johnson Form 10-K for fiscal 2025 (year ended 28 December 2025) - Item 1A risk factors, Note 19 legal proceedings (talc, Innovative Health, Auris, Tracleer) and the Inflation Reduction Act. — FY2025 · publ. 11 February 2026 · source ↗
  5. ReportedThe company lists its ability to successfully separate the orthopaedics business among its risk factors, and the target window of 18 to 24 months from October 2025 ends in 2027.
    Johnson & Johnson announcement of its intent to separate the Orthopaedics business (DePuy Synthes), Form 8-K exhibit 99.3. — October 2025 · publ. 14 October 2025 · source ↗
  6. ReportedIn June 2026 three relators filed an amended False Claims Act complaint in Florida alleging that the company and DePuy Synthes, along with a hospital operator and two medical centres, caused the submission of false claims.
    Johnson & Johnson Form 10-Q for the quarter ended 28 June 2026 - segment income, talc, net debt, repurchases and equity. — Q2 2026 · publ. 23 July 2026 · source ↗
  7. ReportedJ&J excludes orthopaedics separation-related items from adjusted earnings, $258 million in the second quarter and $377 million in the first half of 2026.
    Johnson & Johnson second-quarter 2026 supplementary sales data, statement of earnings and non-GAAP reconciliation, Form 8-K exhibit 99.2 - statement of earnings and non-GAAP reconciliation. — Q2 2026 · publ. 15 July 2026 · source ↗
Sources
Generated September 24, 2026